Clinico-pharmacological aspects of metoprolol use

2013 ◽  
Vol 10 (4) ◽  
pp. 80-83
Author(s):  
G S Anikin ◽  
I M Chernova ◽  
V G Vinokurov
Keyword(s):  
Heart Failure ◽  
Coronary Artery Disease ◽  
Review Article ◽  
Metoprolol Tartrate ◽  
Metoprolol Succinate ◽  
Treatment Of Hypertension ◽  
Cardiovascular Pathologies ◽  
Artery Disease

Over the years b-blocker metoprolol is one of the commonly prescribed drugs for the treatment of various cardiovascular pathologies . The following review article discusses the classification of b-blockers , and pharmacokinetics of two metoprolol forms available on the market today: metoprolol tartrate (Vasocardin, Corvitolum, Egilok ) and metoprolol succinate (Betaloc ZOK). The role of metoprolol in the treatment of hypertension, coronary artery disease and heart failure is described here as well.

HFrEF other treatment: revascularization

ESC CardioMed ◽  
2018 ◽  
pp. 1881-1884
Author(s):  
Eric Velazquez ◽  
Mark C. Petrie
Keyword(s):  
Quality Of Life ◽  
Heart Failure ◽  
Coronary Artery Disease ◽  
Controlled Clinical Trial ◽  
Randomized Controlled Clinical Trial ◽  
Common Cause ◽  
Reduced Ejection Fraction ◽  
Artery Disease

Although coronary artery disease is the most common cause of heart failure with reduced ejection fraction (HFrEF), the role of revascularization as a treatment strategy to improve survival, reduce morbidity, and enhance the quality of life has only begun to be investigated in recent years. To date, a sole randomized controlled clinical trial has been completed. This chapter summarizes what is currently known and what is unknown with respect to revascularization for the treatment of HFrEF.

The Role of Coronary Artery Disease in Heart Failure

2014 ◽  
Vol 10 (2) ◽  
pp. 353-365 ◽  
Author(s):  
Anuradha Lala ◽  
Akshay S. Desai
Keyword(s):  
Heart Failure ◽  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Artery Disease

scholarly journals Hibernating Myocardium and Role of 18F FDG PET Cardiac Imaging – A review

2018 ◽  
Vol 20 (1) ◽  
pp. 45
Author(s):  
Raihan Hussain
Keyword(s):  
Coronary Artery Disease ◽  
Functional Recovery ◽  
Fdg Pet ◽  
Review Article ◽  
Hibernating Myocardium ◽  
Clinical Implications ◽  
Tissue Viability ◽  
18F Fdg ◽  
Artery Disease

<p>The term “Hibernation” is a challenging term but not infrequently used in Nuclear Cardiology. It often is used synonymously for tissue viability, although technically there are some differences. Viability is a prospective definition, but it does not imply evidence of functional recovery after interventions whereas hibernation is a retrospective definition based on evidence of functional recovery after interventions. But for practical clinical purposes both carries the similar meaning. The aim of this review article is to summarize our current understanding of the concept of hibernation and its clinical implications in patients with coronary artery disease (CAD) and the role of FDG PET study in its proper evaluation.</p><p>Bangladesh J. Nuclear Med. 20(1): 45-50, January 2017</p>

Sign in / Sign up

Export Citation Format

Share Document